The U.S. Food and Drug Administration (FDA) has accepted for Priority Review a supplemental Biologics License Application (sBLA) for Merck's VAXNEUVANCE vaccine for the prevention of invasive pneumococcal disease in children six weeks through 17 years of age. The FDA set a Prescription Drug User Fee Act date of April 1, 2022.